Tel: 1-631-504-6093
Email:
Awesome Features1111

Slide Title 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas pulvinar nibh purus, eget convallis erat efficitur eget.

Read More

Awesome Features1111

This is description for slide three1111

Read More

Heavy news for diabetes! Johnson & Johnson Invokana approved for use in patients with type 2 diabetes and diabetic nephropathy

Johnson & Johnson (JNJ) ‘s Janssen Pharmaceuticals has announced that Health Canada has approved a new indication for the glucose-lowering drug Invokana (canagliflozin): Complementary drugs for standard care therapies for […]

Read More →

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]

Read More →